Yes, orforglipron is an oral GLP-1 receptor agonist currently under development, showing promising results in clinical trials for glycemic control and weight loss
Frequently asked questions Can I use the same retatrutide vial for different dose levels during titration
It also works well as a light lunch or dinner
The second co-primary endpoint was a four-step hierarchical analysis including (in order) death from any cause, CV-related hospitalization, the change from baseline in the N-terminal proB-type natriuretic peptide (NT-proBNP) level, and the change from baseline in the 6MWD after 30 months of treatment, which produced a win ratio of 1.8 (p 70 years, prior treatment with chemotherapy or radiation therapy, environmental radiation exposure, and certain genetic conditions (e.g., Down syndrome)
doi: 10.1210/jendso/bvad074, 17 ChangK
Robert Glatter, MD, an emergency physician at Lenox Hill Hospital in New York City and assistant professor at Zucker School of Medicine, told Healthline that these findings support the idea that some patients may have partial biologic resistance to incretin-based therapies. He added that genetics explains only part of the treatment differences and that routine pharmacogenomic screening is not yet ready for widespread clinical use. The same article noted that this PAM research looked at bloodsugar control, not weight loss, and GLP1 drugs are typically prescribed at higher doses for obesity than for diabetes
